Please login to the form below

Not currently logged in
Email:
Password:

Christian Pangratz to head up Sterna Biologicals

He joins as CEO having previously served as senior VP for Vectura Group

Christian PangratzClinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian Pangratz, who joins the firm from Vectura Group, where he served as senior vice president of business development.

He brings over 25 years of life science experience to his new role at the German firm, with expertise in the areas of strategic planning, corporate and business development, alliance and project management, new product planning, marketing and sales.

Jonas Renz, managing director of Sterna, said: “Christian is a proven senior executive with extensive leadership experience and an impressive track record.

“He was instrumental in a number of successful business transformations and high-value transactions across various therapeutic areas that are highly relevant to Sterna.”

Prior to his time with the Vectura Group, Pangratz served as a non-executive director on SkyePharma’s board and before this he was executive vice president of business development at the company.

He has also held roles for Nektar Therapeutics, Bayer and Pfizer.

Commenting on his new move, Pangratz said: “I am delighted to be joining Sterna at such an exciting time.

“Within the past ten years, the company has grown into an accomplished immunology player with four promising phase II programmes and is now poised for its next strategic move.”

7th February 2018

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics